Free tool
FAERS Monitor: Cystagon
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020392 or its brand name (Cystagon, Cysteamine Bitartrate). Reports on generic versions are filed under their own applications.
Reports
350
Serious
237
68% of reports
Hospitalization
139
Death reported
34
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting38
- diarrhoea22
- nausea21
- off label use21
- eye irritation17
- abdominal pain15
- treatment noncompliance15
- eye pain14
- headache14
- pneumonia12
- abdominal pain upper11
- decreased appetite11
- ocular hyperaemia11
- product odour abnormal10
- visual impairment10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 10 |
| 2005 | 2 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 7 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 7 |
| 2012 | 7 |
| 2013 | 1 |
| 2014 | 26 |
| 2015 | 11 |
| 2016 | 10 |
| 2017 | 24 |
| 2018 | 26 |
| 2019 | 24 |
| 2020 | 26 |
| 2021 | 17 |
| 2022 | 42 |
| 2023 | 33 |
| 2024 | 29 |
| 2025 | 22 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,809 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product odour abnormalSignal | 10 | 57.4 | 31.2 | 499 |
| eye irritationSignal | 17 | 17.8 | 11.2 | 253 |
| treatment noncomplianceSignal | 15 | 16.5 | 10.0 | 203 |
| eye painSignal | 14 | 14.9 | 8.9 | 169 |
| ocular hyperaemiaSignal | 11 | 13.9 | 7.8 | 120 |
| vomitingSignal | 38 | 4.9 | 3.6 | 115 |
| visual impairmentSignal | 10 | 4.8 | 2.6 | 27 |
| abdominal painSignal | 15 | 3.9 | 2.4 | 30 |
| abdominal pain upperSignal | 11 | 3.2 | 1.8 | 15 |
| decreased appetiteSignal | 11 | 2.8 | 1.6 | 12 |
| pneumoniaSignal | 12 | 2.2 | 1.3 | 7 |
| diarrhoeaSignal | 22 | 2.0 | 1.4 | 11 |
| nausea | 21 | 1.6 | 1.1 | 4 |
| off label use | 21 | 1.4 | 1.0 | 3 |
| headache | 14 | 1.3 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.